Abstract
Eisenmenger syndrome is associated with irreversible increase in pulmonary vascular resistance causing reduced survival. Bosentan, a non-selective endothelin receptor antagonist is the commonly used specific pulmonary arterial hypertension drug in Eisenmenger syndrome. In this paper, we present a case of recurrent gastrointestinal bleeding in a 23-year-old female with Eisenmenger syndrome who was only under bosentan treatment, which has not been reported previously. Most common adverse effect of bosentan is elevation in the liver enzymes however, bleeding complication is very rare. On the contrary, it was proposed that bosentan might be a potential protector against hyperacidity and mucosal erosion that occur as a consequence of stress. Although the mechanistic relationship of bleeding tendency and role of Eisenmenger syndrome concomitant with bosentan treatment is far from conclusive statement for now, this association warrants and should draw attention of clinicians and researches in this field.
Keywords: Bosentan, congenital heart disease, eisenmenger, gastrointestinal bleeding, pulmonary hypertension.
Current Drug Safety
Title:Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Volume: 8 Issue: 4
Author(s): Ibrahim Sari, Hakan Cam, M. Sait Dag, Erdal Durmus, Tarik Kivrak, Kursat Tigen and Vedat Davutoglu
Affiliation:
Keywords: Bosentan, congenital heart disease, eisenmenger, gastrointestinal bleeding, pulmonary hypertension.
Abstract: Eisenmenger syndrome is associated with irreversible increase in pulmonary vascular resistance causing reduced survival. Bosentan, a non-selective endothelin receptor antagonist is the commonly used specific pulmonary arterial hypertension drug in Eisenmenger syndrome. In this paper, we present a case of recurrent gastrointestinal bleeding in a 23-year-old female with Eisenmenger syndrome who was only under bosentan treatment, which has not been reported previously. Most common adverse effect of bosentan is elevation in the liver enzymes however, bleeding complication is very rare. On the contrary, it was proposed that bosentan might be a potential protector against hyperacidity and mucosal erosion that occur as a consequence of stress. Although the mechanistic relationship of bleeding tendency and role of Eisenmenger syndrome concomitant with bosentan treatment is far from conclusive statement for now, this association warrants and should draw attention of clinicians and researches in this field.
Export Options
About this article
Cite this article as:
Sari Ibrahim, Cam Hakan, Dag Sait M., Durmus Erdal, Kivrak Tarik, Tigen Kursat and Davutoglu Vedat, Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan, Current Drug Safety 2013; 8 (4) . https://dx.doi.org/10.2174/1574886319999990001
DOI https://dx.doi.org/10.2174/1574886319999990001 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Cardiovascular Complications in Patients with Turner’s Syndrome
Current Pharmaceutical Design Pathophysiological Role of Pigment Epithelium-Derived Factor (PEDF) in Hepatic Disorders
Current Medicinal Chemistry Editorial (Thematic Issue: Novel Agents in the Treatment of Osteoporosis and Its Complications)
Current Drug Targets Alveolar Capillary Dysplasia: A Lethal Developmental Lung Malformation
Current Respiratory Medicine Reviews Hydrogen Sulfide Regulates Intracellular Ca2+ Concentration in Endothelial Cells From Excised Rat Aorta
Current Pharmaceutical Biotechnology The Relationships between the Transforming Growth Factor-β 1, Age and the Ultrasound Parameters of Arterial Wall
Vascular Disease Prevention (Discontinued) Uric Acid in Metabolic and Cerebrovascular Disorders: A Review
Current Vascular Pharmacology Editorial from Guest Editor [Hot Topic: Searching for Early Stages in Pathophysiology of Lung Disease: Cell Microenvironment (Guest Editor: Giuseppe Miserocchi)]
Current Respiratory Medicine Reviews Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design Reversal of Diabetes and Metabolic Disorders After Bariatric Surgery
Current Nutrition & Food Science Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models
Current Pharmaceutical Design Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder
Current Alzheimer Research Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design Influence of Vanin-1 and Catalytic Products in Liver During Normal and Oxidative Stress Conditions
Current Medicinal Chemistry Pharmacogenetic Study of CYP2C19 Variation and Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Atherothromboticrisk Patients in Thailand
Current Pharmacogenomics and Personalized Medicine Sunitinib in the Treatment of Thyroid Cancer
Current Medicinal Chemistry Hydroethanolic Extract of <i>Lampaya Medicinalis</i> Phil. (<i>Verbenaceae</i>) Decreases Proinflammatory Marker Expression in Palmitic Acid-exposed Macrophages
Endocrine, Metabolic & Immune Disorders - Drug Targets Which Drugs for the Control of Fever in Critical Patients
Current Drug Targets